3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Acromegaly
2
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Neuroendocrine Tumors in Lung
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Gigantism
1
Gastrointestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoid Tumor
1
Interventions
Docetaxel
56
Prednisone
36
enzalutamide
25
Leuprolide
24
Magnetic Resonance Spectroscopy
19
Abiraterone Acetate
19
bicalutamide
17
Radiotherapy
15
Goserelin
15
abiraterone
12
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
11
olaparib
9
Androgen Antagonists
9
gallium 68 PSMA-11
8
cabazitaxel
8
Radiotherapy, Intensity-Modulated
8
Metformin
8
Ketoconazole
8
Gonadotropin-Releasing Hormone
8
Cyclophosphamide
8
apalutamide
7
Doxorubicin
7
luprolide acetate gel depot
6
cabozantinib
6
Radiosurgery
6
Estramustine
6
Dexamethasone
6
Calcitriol
6
Biopsy
6
pembrolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Prostatic Neoplasms
×
lanreotide
×
Clear all
NCT01313273
2019-11-22
POSEIDON
Ipsen
Phase 3
Terminated
3 enrolled
4 charts